RosetteSep Human ILC2 Enrich, 10mL

STEMCELL Technologies offers an immunodensity-based negative selection cocktail designed to enrich human ILC2 (type 2 innate lymphoid) cells from whole blood at larger scale. The reagent works by forming rosettes between unwanted cells and erythrocytes via tetrameric antibody complexes (TACs) that recognize non-ILC2s and glycophorin A on red blood cells. Following density gradient centrifugation, the unwanted cells pellet with the red blood cells while the ILC2 population is collected as a highly enriched fraction at the plasma–density gradient interface.

The protocol is column-free and suitable for whole blood or PBMC inputs, preserving cell phenotype and function for downstream assays and culture. According to the manufacturer, starting with fresh whole blood, the ILC2 content (defined as Lin-CD45+ CD294+ CD127+ CD161+) of the enriched fraction typically ranges from 0.44 - 53%; in one example, the percentages of ILC2s in the start and final enriched fractions are 0.02% and 10.1%, respectively. The reagent should be refrigerated and protected from freezing, and is intended for research use only — not for clinical diagnostic or therapeutic applications.